[시장보고서]세계의 고안압증 치료 시장 - 산업규모, 점유율, 동향, 기회, 예측, 유형별, 투여경로별, 유통채널별, 지역별, 경쟁별(2020-2030년)

세계의 고안압증 치료 시장 - 산업규모, 점유율, 동향, 기회, 예측, 유형별, 투여경로별, 유통채널별, 지역별, 경쟁별(2020-2030년)

Ocular Hypertension Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Route Of Administration, By Distribution Channel, By Region & Competition, 2020-2030F

상품코드 : 1692270

리서치사 : TechSci Research

발행일 : 2025년 03월

페이지 정보 : 영문 185 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,279,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 7,674,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 11,163,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

고안압증 치료 세계 시장 규모는 2024년에 36억 7,000만 달러로 평가되었으며, 2030년까지의 연평균 성장률(CAGR)은 3.82%를 나타낼 것으로 예상됩니다. 최근, 고안압증의 유병률이 상승하고 진보된 치료 솔루션에 대한 수요가 높아지고 있는 것을 배경으로, 이 시장은 큰 발전을 이루고 있습니다. 고안압증은 안압의 상승을 특징으로 하며 방치하면 녹내장에 이를 수 있으며 세계적으로 돌이킬 수 없는 실명의 주요 원인 중 하나가 되고 있습니다. 그 결과, 고안압 치료 시장은 안과 의료 분야의 중요한 부문입니다. 예를 들어, 2024년 1월, 인디애나 대학 의과 대학의 연구자들은 녹내장의 획기적인 치료법을 개발하는 혁신적인 이니셔티브를 시작했습니다. 이 연구는 미국 국립 안병 연구소로부터 200만 달러의 R01 보조금을 받았습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	36억 7,000만 달러
시장 규모 : 2030년	45억 6,000만 달러
CAGR : 2025-2030년	3.82%
급성장 부문	온라인 약국
최대 시장	북미

주요 시장 성장 촉진요인

노화

주요 시장 과제

과소 진단 및 인식 부족

주요 시장 동향 :

낮은 침습 수술 기술

시장 규모와 예측
- 금액별
시장 점유율 및 예측
- 유형별(고안압증, 녹내장)
- 투여 경로별(경구, 비경구, 기타)
- 유통 채널별(소매 약국, 온라인 약국, 기타)
- 지역별
- 기업별(2024년)
시장 맵
- 유형별
- 투여 경로별
- 유통 채널별
- 지역별

제5장 아시아태평양의 고안압증 치료 시장 전망

시장 규모와 예측
- 금액별
시장 점유율 및 예측
아시아태평양 : 국가별 분석
- 중국
- 인도
- 호주
- 일본
- 한국

제6장 유럽의 고안압증 치료 시장 전망

시장 규모와 예측
시장 점유율 및 예측
유럽 : 국가별 분석
- 독일
- 스페인
- 이탈리아
- 영국

제7장 북미의 고안압증 치료 시장 전망

시장 규모와 예측
시장 점유율 및 예측
북미 : 국가별 분석
- 멕시코
- 캐나다

제8장 남미의 고안압증 치료 시장 전망

시장 규모와 예측
시장 점유율 및 예측
남미 : 국가별 분석
- 아르헨티나
- 콜롬비아

제9장 중동 및 아프리카의 고안압증 치료 시장 전망

시장 규모와 예측
시장 점유율 및 예측
중동 및 아프리카: 국가별 분석
- 사우디아라비아
- 아랍에미리트(UAE)

제10장 시장 역학

성장 촉진요인
과제

제11장 시장 동향과 발전

최근 동향
제품 출시
합병과 인수

제12장 세계의 고안압증 치료 시장 : SWOT 분석

제13장 Porter's Five Forces 분석

업계 내 경쟁
신규 진입의 가능성
공급자의 힘
고객의 힘
대체품의 위협

제14장 경쟁 구도

Angelini Spa
Laboratorios Sophia
Neurim Pharmaceuticals Ltd
Nicox SA
Novartis AG.
Aerie Pharmaceuticals, Inc.
Abbvie, Inc
Angelini Pharma Spa
Chong Kun Dang pharmaceutical Corp
Lee Pharma Ltd

제15장 전략적 제안

제16장 기업 소개와 면책사항

SHW

영문 목차

영문목차

The global Ocular Hypertension Treatment Market was valued at USD 3.67 billion in 2024 and is projected to experience robust growth during the forecast period, with a compound annual growth rate (CAGR) of 3.82% through 2030. The market has seen significant development in recent years, driven by the rising prevalence of ocular hypertension and the increasing demand for advanced therapeutic solutions. Ocular hypertension is characterized by elevated intraocular pressure, which, if left untreated, can lead to glaucoma-one of the leading causes of irreversible blindness worldwide. As a result, the ocular hypertension treatment market is a critical segment of the ophthalmic healthcare sector. For example, in January 2024, researchers at Indiana University School of Medicine launched an innovative initiative to develop groundbreaking therapy for glaucoma, supported by a USD 2 million R01 grant from the National Eye Institute.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 3.67 Billion
Market Size 2030	USD 4.56 Billion
CAGR 2025-2030	3.82%
Fastest Growing Segment	Online Pharmacy
Largest Market	North America

Key Market Drivers:

Aging Population

The growing aging population is a key driver of the expanding global ocular hypertension treatment market. As individuals age, they become more susceptible to ocular hypertension due to age-related changes in the eye's drainage system, which can hinder the flow of aqueous humor and increase intraocular pressure. The World Health Organization forecasts that the global population aged 60 and older will more than double by 2050, reaching nearly 2.1 billion people. This demographic shift will result in a rise in the prevalence of ocular hypertension and glaucoma among the elderly, creating a larger patient base in need of treatment. As the population ages, there will be an increased demand for both pharmaceutical and surgical interventions, including minimally invasive procedures like Micro-Invasive Glaucoma Surgery (MIGS). These treatments offer less invasive and more efficient solutions for managing intraocular pressure. Consequently, the global ocular hypertension treatment market is positioned for steady growth, catering to the rising healthcare needs of older individuals and contributing to better vision preservation and reduced blindness rates.

Key Market Challenges:

Underdiagnosis and Lack of Awareness

Ocular hypertension is often a silent condition, with no obvious symptoms, making it challenging to detect early. Many individuals are unaware of the condition and its potential progression to glaucoma, which leads to a delay in diagnosis and intervention. This lack of awareness poses a significant barrier to market growth, as untreated ocular hypertension can advance to glaucoma, resulting in irreversible vision loss. Public ignorance about the importance of regular eye check-ups further complicates early detection efforts. Raising awareness about ocular hypertension and its connection to glaucoma is essential for capturing potential patients early, when treatments are most effective. Healthcare professionals, ophthalmologists, and public health campaigns must play a key role in educating individuals about the risks of ocular hypertension and the need for proactive eye care.

Key Market Trends:

Minimally Invasive Surgical Techniques

Minimally invasive surgical techniques are transforming the treatment landscape for ocular hypertension. Traditionally, managing elevated intraocular pressure involved more invasive surgeries, often with longer recovery times and higher risks. However, the development of Micro-Invasive Glaucoma Surgery (MIGS) has introduced a less invasive approach that reduces surgical trauma while targeting the underlying causes of elevated intraocular pressure. MIGS has numerous benefits for both patients and healthcare providers, including shorter recovery periods, lower complication rates, and improved patient outcomes. The growing adoption of MIGS is expected to continue driving the ocular hypertension treatment market, providing a shift toward more efficient and patient-friendly treatment options.

Key Market Players:

Angelini Spa
Laboratorios Sophia
Neurim Pharmaceuticals Ltd
Nicox SA
Novartis AG
Aerie Pharmaceuticals, Inc.
AbbVie, Inc.
Angelini Pharma S.p.a.
Chong Kun Dang Pharmaceutical Corp
Lee Pharma Ltd

Report Scope:

This report segments the global ocular hypertension treatment market into various categories and provides a detailed analysis of trends:

By Type:

Intraocular Hypertension
Glaucoma

By Route of Administration:

Oral
Parenteral
Other

By Distribution Channel:

Retail Pharmacy
Online Pharmacy
Other

By Region:

North America: United States, Canada, Mexico
Europe: France, United Kingdom, Italy, Germany, Spain
Asia-Pacific: China, India, Japan, Australia, South Korea
South America: Brazil, Argentina, Colombia
Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape:

This section provides a comprehensive analysis and profiling of major companies operating in the global ocular hypertension treatment market.

Available Customizations:

TechSci Research offers tailored customization options for this market report, allowing adjustments to meet specific company needs. Customization options include detailed analysis and profiling of up to five additional market players.

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Global Ocular Hypertension Treatment Market Outlook

4.1. Market Size & Forecast
- 4.1.1. By Value
4.2. Market Share & Forecast
- 4.2.1. By Type (Intraocular Hypertension, Glaucoma)
- 4.2.2. By Route Of Administration (Oral, Parenteral, Other)
- 4.2.3. By Distribution Channel (Retail Pharmacy, Online Pharmacy, Other)
- 4.2.4. By Region
- 4.2.5. By Company (2024)
4.3. Market Map
- 4.3.1. By Type
- 4.3.2. By Route Of Administration
- 4.3.3. By Distribution Channel
- 4.3.4. By Region

5. Asia Pacific Ocular Hypertension Treatment Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type
- 5.2.2. By Route Of Administration
- 5.2.3. By Distribution Channel
- 5.2.4. By Country
5.3. Asia Pacific: Country Analysis
- 5.3.1. China Ocular Hypertension Treatment Market Outlook
  - 5.3.1.1. Market Size & Forecast
    - 5.3.1.1.1. By Value
  - 5.3.1.2. Market Share & Forecast
    - 5.3.1.2.1. By Type
    - 5.3.1.2.2. By Route Of Administration
    - 5.3.1.2.3. By Distribution Channel
- 5.3.2. India Ocular Hypertension Treatment Market Outlook
  - 5.3.2.1. Market Size & Forecast
    - 5.3.2.1.1. By Value
  - 5.3.2.2. Market Share & Forecast
    - 5.3.2.2.1. By Type
    - 5.3.2.2.2. By Route Of Administration
    - 5.3.2.2.3. By Distribution Channel
- 5.3.3. Australia Ocular Hypertension Treatment Market Outlook
  - 5.3.3.1. Market Size & Forecast
    - 5.3.3.1.1. By Value
  - 5.3.3.2. Market Share & Forecast
    - 5.3.3.2.1. By Type
    - 5.3.3.2.2. By Route Of Administration
    - 5.3.3.2.3. By Distribution Channel
- 5.3.4. Japan Ocular Hypertension Treatment Market Outlook
  - 5.3.4.1. Market Size & Forecast
    - 5.3.4.1.1. By Value
  - 5.3.4.2. Market Share & Forecast
    - 5.3.4.2.1. By Type
    - 5.3.4.2.2. By Route Of Administration
    - 5.3.4.2.3. By Distribution Channel
- 5.3.5. South Korea Ocular Hypertension Treatment Market Outlook
  - 5.3.5.1. Market Size & Forecast
    - 5.3.5.1.1. By Value
  - 5.3.5.2. Market Share & Forecast
    - 5.3.5.2.1. By Type
    - 5.3.5.2.2. By Route Of Administration
    - 5.3.5.2.3. By Distribution Channel

6. Europe Ocular Hypertension Treatment Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Route Of Administration
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
6.3. Europe: Country Analysis
- 6.3.1. France Ocular Hypertension Treatment Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Route Of Administration
    - 6.3.1.2.3. By Distribution Channel
- 6.3.2. Germany Ocular Hypertension Treatment Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Route Of Administration
    - 6.3.2.2.3. By Distribution Channel
- 6.3.3. Spain Ocular Hypertension Treatment Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Route Of Administration
    - 6.3.3.2.3. By Distribution Channel
- 6.3.4. Italy Ocular Hypertension Treatment Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Type
    - 6.3.4.2.2. By Route Of Administration
    - 6.3.4.2.3. By Distribution Channel
- 6.3.5. United Kingdom Ocular Hypertension Treatment Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Type
    - 6.3.5.2.2. By Route Of Administration
    - 6.3.5.2.3. By Distribution Channel

7. North America Ocular Hypertension Treatment Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Route Of Administration
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
7.3. North America: Country Analysis
- 7.3.1. United States Ocular Hypertension Treatment Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Route Of Administration
    - 7.3.1.2.3. By Distribution Channel
- 7.3.2. Mexico Ocular Hypertension Treatment Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Route Of Administration
    - 7.3.2.2.3. By Distribution Channel
- 7.3.3. Canada Ocular Hypertension Treatment Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Route Of Administration
    - 7.3.3.2.3. By Distribution Channel

8. South America Ocular Hypertension Treatment Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Route Of Administration
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
8.3. South America: Country Analysis
- 8.3.1. Brazil Ocular Hypertension Treatment Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Route Of Administration
    - 8.3.1.2.3. By Distribution Channel
- 8.3.2. Argentina Ocular Hypertension Treatment Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Route Of Administration
    - 8.3.2.2.3. By Distribution Channel
- 8.3.3. Colombia Ocular Hypertension Treatment Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Route Of Administration
    - 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Ocular Hypertension Treatment Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Route Of Administration
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
9.3. MEA: Country Analysis
- 9.3.1. South Africa Ocular Hypertension Treatment Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Route Of Administration
    - 9.3.1.2.3. By Distribution Channel
- 9.3.2. Saudi Arabia Ocular Hypertension Treatment Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Route Of Administration
    - 9.3.2.2.3. By Distribution Channel
- 9.3.3. UAE Ocular Hypertension Treatment Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Route Of Administration
    - 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

10.1. Drivers
10.2. Challenges

11. Market Trends & Developments

11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions

12. Global Ocular Hypertension Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product

14. Competitive Landscape

14.1. Angelini Spa
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (In case of listed)
- 14.1.5. Recent Developments
- 14.1.6. SWOT Analysis
14.2. Laboratorios Sophia
14.3. Neurim Pharmaceuticals Ltd
14.4. Nicox SA
14.5. Novartis AG.
14.6. Aerie Pharmaceuticals, Inc.
14.7. Abbvie, Inc
14.8. Angelini Pharma S.p.a.
14.9. Chong Kun Dang pharmaceutical Corp
14.10. Lee Pharma Ltd